NasdaqGS:IBRXBiotechs
ImmunityBio Gains First Asian ANKTIVA Nod As Cell Therapy Story Builds
ImmunityBio (NasdaqGS:IBRX) received its first Asian regulatory approval for ANKTIVA in Macau, marking the product’s initial foothold in the region.
The company reported positive safety and feasibility data for its autologous memory cytokine enhanced NK (M ceNK) cell therapy platform, following completion of key manufacturing engineering and clinical translation work.
For investors tracking ImmunityBio, these updates come as the stock trades at $8.47, with very large year to date returns...